State Street Corp Has $6.35 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

State Street Corp reduced its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 39.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,192,436 shares of the biotechnology company’s stock after selling 2,088,430 shares during the period. State Street Corp’s holdings in Heron Therapeutics were worth $6,353,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Clearline Capital LP boosted its stake in Heron Therapeutics by 48.9% in the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock valued at $4,431,000 after buying an additional 731,246 shares in the last quarter. Congress Park Capital LLC boosted its holdings in shares of Heron Therapeutics by 25.3% during the 3rd quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock valued at $3,936,000 after acquiring an additional 399,577 shares in the last quarter. Marshall Wace LLP grew its position in Heron Therapeutics by 256.2% during the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock worth $6,164,000 after acquiring an additional 1,266,697 shares during the last quarter. AQR Capital Management LLC increased its holdings in Heron Therapeutics by 1,460.9% in the 2nd quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock worth $2,125,000 after purchasing an additional 568,238 shares in the last quarter. Finally, Panagora Asset Management Inc. boosted its stake in shares of Heron Therapeutics by 49.8% during the second quarter. Panagora Asset Management Inc. now owns 562,228 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 186,802 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, December 4th. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 19th.

Heron Therapeutics Stock Performance

Shares of HRTX opened at $1.55 on Friday. The firm has a market cap of $235.75 million, a P/E ratio of -8.61 and a beta of 1.67. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The business has a 50-day moving average of $1.53 and a 200 day moving average of $2.14.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter in the prior year, the company earned ($0.17) earnings per share. As a group, research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.